Premium
Sirolimus for the treatment of juvenile nasopharyngeal angiofibroma
Author(s) -
Fernández Karen S.,
Alarcon Alessandro,
Adams Denise M.,
Hammill Adrienne M.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28162
Subject(s) - juvenile nasopharyngeal angiofibroma , medicine , sirolimus , discovery and development of mtor inhibitors , radiation therapy , angiofibroma , radiology , juvenile , surgery , pi3k/akt/mtor pathway , apoptosis , biology , biochemistry , chemistry , genetics
Abstract Juvenile nasopharyngeal angiofibroma (JNA) is a pathologically benign yet locally aggressive and destructive tumor that develops in the choana and nasopharynx. Historical treatment of JNA has included embolization, surgical resection, and radiation. Here, we describe three patients who received therapy with the mTOR inhibitor sirolimus with improvement in clinical symptoms, imaging, and overall well‐being.